Question 1

Who are the top researchers at NexImmune (United States)?

Accepted Answer

Ranked on the quality score, David Langan and Lauren Suarez lead among researchers whose main affiliation is NexImmune (United States).

Question 2

What are the most cited papers from NexImmune (United States)?

Accepted Answer

The most cited paper from NexImmune (United States) is "Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study" (Christopher Edward Brightling, Eugene R. Bleecker, Reynold A. Panettieri et al., 2014), with 316 citations. Next come "Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease." (99) and "A randomised, placebo-controlled trial of anti–interleukin-1 receptor 1 monoclonal antibody MEDI8968 in chronic obstructive pulmonary disease" (97).

Question 3

Which research topics does NexImmune (United States) publish most on?

Accepted Answer

By volume in 2022-now: CAR-T cell therapy research, Immunotherapy and Immune Responses, Immune Cell Function and Interaction and Endoplasmic Reticulum Stress and Disease.

Question 4

Which fields of science does NexImmune (United States) work in?

Accepted Answer

In all years, 61% of research at NexImmune (United States) is in Life Sciences, 35% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (34%), Medicine (33%), Immunology and Microbiology (25%). It does 2.4× the world's share of Life Sciences.

Question 5

Is NexImmune (United States)'s research output growing?

Accepted Answer

Output in 2022-2025 was 1% lower than in 2018-2021.